# Mithradote Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mithradote-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.mithradote.com/
- Total disclosed funding: $1M
- Latest round: Seed (Oct 2, 2024)
- Investors on record: 2

## About

Founded in 2023 and based in California, US, Mithradote Bio, Inc. develops M-101, a sublingual pan-antidote aimed at counteracting the effects of drug-facilitated sexual assault. The company was founded by its CEO, Sophia Lee. In October 2024, Mithradote Bio, Inc. raised USD 1 million in seed funding co-led by TAHO Pharmaceuticals Ltd. and Vickers Venture Partners.

Mithradote Bio engages in developing M-101, a novel sublingual pan-antidote that targets benzodiazepines, Z drugs, and other GABA agonists to counteract drug-facilitated sexual assault. M-101 is designed for rapid absorption and is intended for personal use, allowing individuals at risk to carry it discreetly. The primary users are individuals in social settings who may be vulnerable to such assaults. The company aims to expand its market reach in urban areas with higher incidences of these crimes, focusing on major cities in North America and Europe.

Mithradote Bio utilizes a direct-to-consumer sales model for its flagship product, M-101, allowing consumers to purchase the antidote directly from the company. The firm is exploring potential partnerships with healthcare providers to increase its distribution footprint, which could include bulk purchase options or subscription models.

The organization plans to use the October 2024 funding to further develop the M-101 self-administered antidote.

## Funding rounds

- Seed, Oct 2, 2024, $1M — Vickers Venture Partners, TAHO Pharmaceuticals Ltd.

## Investors

- Vickers Venture Partners (https://capitalatlas.ai/funds/vickers-venture-partners) — Seed
- TAHO Pharmaceuticals Ltd. — Seed